| 501 |
11669467 | Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. | 2001 Sep 28 |
1 |
| 502 |
11696815 | Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. | 2001 Dec |
1 |
| 503 |
11760783 | Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. | 2001 Nov |
1 |
| 504 |
11770869 | Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers. | 2001 Nov |
1 |
| 505 |
11890515 | The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. | 2001 Oct |
1 |
| 506 |
10654914 | Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. | 2000 Jan |
1 |
| 507 |
10693332 | [Effectiveness and adverse effects of sildenafil in erectile dysfunction]. | 2000 Jan 16 |
1 |
| 508 |
10753463 | N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. | 2000 Apr 6 |
2 |
| 509 |
10893544 | New PDE5 inhibitors: more selective than Viagra? | 2000 Aug |
1 |
| 510 |
10899281 | Cardiovascular risk and sildenafil. | 2000 Jul 20 |
2 |
| 511 |
10913932 | Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. | 2000 Aug |
1 |
| 512 |
10953172 | Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum. | 2000 Sep |
1 |
| 513 |
11053205 | Inhibition of neuroeffector transmission in human vas deferens by sildenafil. | 2000 Nov |
1 |
| 514 |
11137498 | Sex and the patient with cardiovascular risk factors: focus on sildenafil. | 2000 Dec 18 |
3 |
| 515 |
11152621 | Cross-regulation of intracellular cGMP and cAMP in cultured human corpus cavernosum smooth muscle cells. | 2000 Jul |
2 |
| 516 |
16107932 | PDE inhibitors--Second William Harvey Research Conference. Drugs with an expanding range of therapeutic uses. 1-3 December 1999, Nice, France. | 2000 Feb |
2 |
| 517 |
10078537 | Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. | 1999 Mar 4 |
7 |
| 518 |
10078538 | Effects of sildenafil citrate on human hemodynamics. | 1999 Mar 4 |
2 |
| 519 |
10078539 | Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. | 1999 Mar 4 |
1 |
| 520 |
10078540 | Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. | 1999 Mar 4 |
2 |
| 521 |
10078541 | Overall cardiovascular profile of sildenafil citrate. | 1999 Mar 4 |
3 |
| 522 |
10385692 | Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. | 1999 Jul |
12 |
| 523 |
10541153 | Sildenafil (Viagra) and ophthalmology. | 1999 Sep-Oct |
4 |
| 524 |
10574925 | Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). | 1999 Dec 3 |
2 |
| 525 |
10584234 | [Pharmacological profiles of sildenafil (VIAGRA) in the treatment of erectile dysfunction: efficacy and drug interaction with nitrate]. | 1999 Oct |
5 |
| 526 |
12567500 | [Mode of action of sildenafil]. | 1999 Dec |
1 |
| 527 |
12973386 | Sildenafil: a new oral therapy for erectile dysfunction. | 1999 Mar |
1 |
| 528 |
9598563 | Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. | 1998 Jun |
5 |
| 529 |
9916601 | Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. | 1998 Nov-Dec |
3 |
| 530 |
8858389 | Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. | 1996 Jun |
2 |